Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CLPT
STRONG SELLClearPoint Neuro, Inc. · Healthcare · United States · $423M · Avg Vol: $13M/d
COMPANY DESCRIPTION
ClearPoint Neuro, Inc. develops and commercializes a neuro-navigation system for minimally invasive brain procedures, alongside a portfolio of specialized therapeutic and drug delivery platforms. Its proprietary ClearPoint system offers real-time MRI-guided navigation, providing surgeons with enhanced precision and control for complex neurological interventions. The company is a specialized medical technology firm focusing on advanced neurosurgical solutions, becoming a key enabler for brain drug and gene delivery.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.6M | 24.0M | 31.4M | 37.0M | 21.6% | 40.6M | 53.1M | 64.1M | 31.7% |
| EPS | -0.68 | -0.90 | -0.70 | -0.90 | — | -0.99 | -1.11 | -0.94 | — |
| Shares | 24.6M | 24.7M | 27.6M | 29.4M | +19.5% | 30.0M | — | — | — |
| Debt | 12.0M | 13.9M | 3.6M | 58.2M | 69.4% | 63.6M | — | — | — |
| Equity | 36.9M | 21.2M | 25.4M | 28.0M | -8.8% | — | — | — | — |
| Op CF | -16.2M | -13.7M | -8.9M | -23.9M | — | -25.7M | — | — | — |
| Inv CF | -10.7M | 8.9M | -0.3M | 0.6M | — | — | — | — | — |
| Fin CF | 0.4M | 0.3M | 6.2M | 50.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CLPT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CLPT | ClearPoint Neuro, Inc.(you) | $423M | 13 | STRONG SELL |
| IMR.AX | Imricor Medical Systems, Inc. | $455M | 15 | STRONG SELL |
| PACB | Pacific Biosciences of California, Inc. | $422M | 6 | STRONG SELL |
| CATX | Perspective Therapeutics, Inc. | $332M | 16 | STRONG SELL |
| MOBI | Mobia Medical, Inc. | $361M | 7 | STRONG SELL |
| CV | CapsoVision, Inc. | $324M | 17 | STRONG SELL |
| TLSI | TriSalus Life Sciences, Inc. | $259M | 16 | STRONG SELL |
| LAB | Standard BioTools Inc. | $326M | 22 | SELL |
| PRCT | PROCEPT BioRobotics Corporation | $950M | 14 | STRONG SELL |
| SGHT | Sight Sciences, Inc. | $267M | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%